Specifically, it modulates CD44 alternative splicing, favoring the conversion from variant isoforms (CD44v) to the standard isoform (CD44s), which drives epithelial-mesenchymal transition (EMT) and enhances invasion and metastasis in triple-negative breast cancer [24, 43, 44]. Here, CD44 is linked to triple-negative breast carcinoma.